ISGIO

Eileen M. O’Reilly, MD, discusses the current treatment landscape for neuroendocrine tumors.

At ISGIO 2020, Michael J. Pishvaian, MD, PhD, discussed the importance of using standard-of-care chemotherapy and to test for actionable mutations in patients with pancreatic cancers, which can identify ways to individualize therapy for these patients.

With the number of targets in gastrointestinal cancer growing, particularly KRAS in colorectal cancer and tumor mutational burden across all gastrointestinal tumors, Andrea Cercek, MD, sought to provide an overview of current and emerging targets during the 17th Annual Meeting of the International Society of Gastrointestinal Oncology.

In an interview with Targeted Oncology following a virtual presentation for the ISGIO 2020, Yelena Janjigian, MD, provided an overview of the role of HER2-targeted therapies in advanced gastric cancer. She also explained the importance of biomarker testing in this space.

Laura Goff, MD, discussed the combination of atezolizumab plus bevacizumab in relation to its effect on the treatment paradigm of hepatocellular carcinoma during a presentation at the 17th Annual Meeting of the International Society of Gastrointestinal Oncology.

In an interview with Targeted Oncology following ISGIO 2020, Elena Chiorean, MD, oncologist, discussed universal genetic testing at the time of diagnosis for patients with pancreatic cancer, a topic she argued on during an ISGIO medical crossfire. She also explained the challenges with execute germline testing setting.

Michael J. Pishvaian, MD, PhD, discusses the key takeaway from his presentation at the 17th Annual Meeting of the International Society of Gastrointestinal Oncology on the role of genetic testing in patients with pancreatic cancer.

Immunotherapy has demonstrated significant benefits in recent large trials, reaching new survival benchmarks for upper gastrointestinal cancers across various settings of disease, according to Jaffer A. Ajani, MD.

As the new chair of the 17th Annual International Society of Gastrointestinal Oncology meeting, Tanios Bekaii-Saab, MD, said that this year’s virtual conference will place particular emphasis on fellows’ education and involvement.